Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
61-75 of 4340 results
Alnylam scraps RNAi drug development over safety concerns
By PBR Staff Writer
Alnylam Pharmaceuticals is stopping the development of revusiran, a therapeutic intended at treating hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM), due to safety concerns.
Drug Research > Drug Discovery & Development > News
Japanese cell biologist Yoshinori Ohsumi wins Nobel Prize in medicine
By PBR Staff Writer
Japanese cell biologist Yoshinori Ohsumi has been awarded the 2016 Nobel Prize in physiology or medicine, for his discoveries of mechanisms for autophagy.
Drug Research > Drug Discovery & Development > News
Recursion Pharmaceuticals raises $12.9m to apply AI to drug discovery
Recursion Pharmaceuticals has raised $12.9m to discover new drugs using artificial intelligence (AI).
Drug Research > Drug Discovery & Development > News
Amgen, Arrowhead to develop gene therapies for cardiovascular disease
By PBR Staff Writer
Amgen said it will acquire a stake in Arrowhead Pharmaceuticals and partner with the company in the development of gene therapies for cardiovascular disease.
Drug Research > Drug Discovery & Development > News
Boehringer, ViraTherapeutics partner to jointly develop oncolytic virus therapy platform
Boehringer Ingelheim and ViraTherapeutics are collaborating to jointly develop a next generation oncolytic virus therapy platform and to investigate ViraTherapeutics’ lead candidate VSV-GP (Vesicular Stomatitis Virus (VSV) glycoprotein (GP)) alone and in combination with other therapies.
Drug Research > Drug Discovery & Development > News
Pfizer closes Medivation acquisition
Pfizer has completed its acquisition of US biopharmaceutical firm Medivation for about $14bn.
Drug Research > Drug Discovery & Development > News
Redx Pharma discovers breakthrough antibiotic compounds
Redx Pharma has discovered a series of compounds that have the potential to create the first novel class of broad-spectrum antibiotics in 30 years.
Drug Research > Drug Discovery & Development > News
C4X Discovery enters into multi-target, risk-sharing alliance with Evotec
C4X Discovery has entered into a multi-target, risk-sharing alliance (the agreement) with Evotec, a drug discovery alliance and development partnership firm.
Drug Research > Drug Discovery & Development > News
Sanofi secures $43m US funding to spur Zika vaccine development
The Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response in the US Department of Health and Human Services is giving Sanofi $43.2m to fund the manufacture of a Zika vaccine for phase II development.
Drug Research > Drug Discovery & Development > News
Turing advances several experimental compounds into pre-clinical development
Turing Pharmaceuticals has advanced several experimental compounds into pre-clinical development.
Drug Research > Drug Discovery & Development > News
Allergan to acquire Tobira Therapeutics in $1.7bn deal
By PBR Staff Writer
Allergan has agreed to acquire clinical-stage biopharmaceutical firm Tobira Therapeutics in a deal worth about $1.7bn.
Drug Research > Drug Discovery & Development > News
Alnylam opens new development and commercial hub in Maidenhead, UK
RNAi therapeutics firm Alnylam Pharmaceuticals has opened a new development and commercial hub in Maidenhead, UK.
Drug Research > Drug Discovery & Development > News
Aerie Pharmaceuticals raises $125m in public offerings
Aerie Pharmaceuticals announced the pricing of a registered underwritten public offering of $75m of shares of its common stock at a price to the public of $29.50 per share, before deducting underwriting discounts and commissions and other estimated offering expenses.
Drug Research > Drug Discovery & Development > News
Peloton Therapeutics completes $52.4m Series D financing round
Peloton Therapeutics, a drug discovery and development firm focused on advancing small molecule cancer therapies, has completed a $52.4m Series D financing round.
Drug Research > Drug Discovery & Development > News
Allergan to buy Vitae Pharmaceuticals for $639m
By PBR Staff Writer
Allergan has agreed to acquire US-based clinical-stage biotechnology firm Vitae Pharmaceuticals for about $639m.
Drug Research > Drug Discovery & Development > News
61-75 of 4340 results